EMA Authorised: Abilify (aripiprazole) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

The EMA authorised Abilify (aripiprazole) by Otsuka Pharmaceutical Netherlands B.V. for schizophrenia and bipolar disorder in the European Union, with decision …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Abilify (aripiprazole)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: Otsuka Pharmaceutical Netherlands B.V.. Decision date: 09/01/2026